Determination of Anti-Spike S1 RBD IgG Values in Healthcare Workers with Inactivated SARS-CoV-2 Vaccine

Year 2024, Volume: 7 Issue: 2, 93 - 97, 01.03.2024

Kardelen Bülbül , Taylan Bozok , Hamide Kaya , Harun Gülbudak , Seda Tezcan Ülger , Gönül Aslan

https://doi.org/10.19127/bshealthscience.1387834

Abstract

Various vaccines have been developed to combat the disease and its complications during the COVID-19 pandemic. Our study aimed to determine COVID-19 antibody titers in healthcare workers who received two doses of Coronavac (Sinovac) vaccine. Access SARS-CoV-2 IgG test (Beckman) was performed on blood samples taken from 186 volunteer healthcare workers who received two doses of Coronavac vaccine at Mersin University Hospital between March and September 2021. Antibody titers were determined by ELISA-based testing. Of the 186 participants included in the study, 47.8% (n = 89) were male and 52.2% (n = 97) were female. The average age is 42.3±8.7 (23-60). A significant difference was detected between the positivity rates of participants aged 40 and under and participants over 40 years of age (<=40; 68.1%, >40; 43.6%, P=0.001). It was observed that the group with the highest positive antibody titer was the 21-30 age groups. It was determined that antibody levels decreased significantly with increasing age (r=-0.203, P=0.005). There were 22 participants with comorbidities. No significant difference was observed in terms of antibody titer in patients with comorbidities compared to healthy individuals. Since our study was a short-term project, it was conducted with a small number of participants. More comprehensive studies are needed.

Keywords

COVID-19, Inactivated vaccine, Antibody

Ethical Statement

Mersin Üniversitesi Klinik Araştırmalar Etik Kurulu'ndan onay alınmıştır. (03/03/2021 tarihli, 05-216 sayılı)

Supporting Institution

Mersin Üniversitesi Bilimsel Araştırma Projeler Birimi

İnaktif SARS-CoV-2 Aşısı Uygulanan Sağlık Çalışanlarında Anti-Spike S1 RBD IgG Değerlerinin Belirlenmesi

Abstract

COVID-19 pandemisi sırasında hastalık ve komplikasyonlarıyla mücadele amacıyla çeşitli aşılar geliştirilmiştir. Çalışmamızda iki doz Coronavac (Sinovac) aşısı uygulanmış sağlık çalışanlarında COVID-19 antikor titrelerinin belirlenmesi amaçlanmıştır. Mart- Eylül 2021 tarihleri arasında Mersin Üniversitesi Hastanesi’nde gönüllü sağlık çalışanlarından iki doz Coronavac aşısı uygulanan 186 kişiden alınan kan örneklerinden Access SARS-CoV-2 IgG testi (Beckman) uygulandı. Antikor titreleri ELISA temelli test ile tespit edildi. Çalışmaya dahil edilen 186 katılımcının %47,8’i (n=89) erkek, %52,2’si (n=97) kadındır. Yaş ortalaması 42,3±8,7 (23-60) ‘tür. 40 yaş ve altı katılımcılar ile 40 yaş üzeri katılımcıların pozitiflik oranları arasında anlamlı farklılık tespit edildi (<=40; %68,1, >40; %43,6, P=0,001). En fazla pozitif antikor titresi olan grup 21-30 yaş grubu olduğu görüldü. Yaş artışı ile birlikte antikor düzeyleri anlamlı şekilde azaldığı belirlendi (r=-0.203, P=0,001). Ek hastalığı olan 22 katılımcı vardır. Ek hastalığı olanlarda, sağlıklı olanlara göre antikor titresi açısından anlamlı farklılık gözlenmedi. Çalışmamız kısa süreli bir proje olduğu için az sayıda katılımcı ile yapılmıştır. Daha geniş kapsamlı yapılacak çalışmalara ihtiyaç vardır.

Keywords

COVID-19, İnaktif aşı, Antikor

References

• Adab P, Haroon S, O’Hara ME, Jordan RE. 2022. Comorbidities and Covid-19. BMJ, 15: 377.
• Alexander JL, Kennedy NA, Ibraheim H, et al. 2022. COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study. Lancet Gastroenterol Hepatol, 7(4): 342-352.
• Anastassopoulou C, Antoni D, Manoussopoulos Y, et al. 2022. Age and sex associations of SARS-CoV-2 antibody responses post BNT162b2 vaccination in healthcare workers: A mixed effects model across two vaccination periods. PLoS One, 17(4): e0266958.
• Bayram A, Demirbakan H, Günel Karadeniz P, Erdoğan M, Koçer I. 2021. Quantitation of antibodies against SARS‐CoV‐2 spike protein after two doses of CoronaVac in healthcare workers. J Med Virol, 93(9): 5560-5567.
• Bichara CDA, Queiroz MAF, da Silva Graça Amoras E, et al. 2021. Assessment of anti-SARS-CoV-2 antibodies post-Coronavac vaccination in the Amazon region of Brazil. Vaccines, 9(10): 1169.
• Binay U, Karakecili F, Barkay O, Gül Ö & Mertoğlu C. 2021. Level of SARS-CoV-2 IgG antibodies after two doses CoronaVac vaccine: Primarily report. J Antivir Antiretrovir, 13(18): 1-4.
• Davarci I, Eryildiz C, Gurcan S. 2021. Sağlık çalışanlarında inaktive SARS-CoV-2 aşısı ile aşılanma sonrası antikor yanıtının değerlendirilmesi [Evaluation of antibody response after vaccination with inactivated SARS-CoV-2 vaccine in healthcare workers]. FLORA, 26(2): 338-43.
• Dinc HO, Saltoglu N, Can G, et al. 2022. Inactive SARS-CoV-2 vaccine generates high antibody responses in healthcare workers with and without prior infection. Vaccine, 40(1): 52-58.
• Dogan M, Kozhaya L, Placek L, et al. 2021. SARS-CoV-2 specific antibody and neutralization assays reveal the wide range of the humoral immune response to virus. Commun Biol, 4(1): 129.
• Dong Y, Dai T, Wei Y, et al. 2020. A systematic review of SARS-CoV-2 vaccine candidates. Signal Transduct Target Ther, 5(1): 237.
• Firestone MJ, Lorentz AJ, Wang X, et al. 2021. First identified cases of SARS-CoV-2 variant B.1.1.7 in Minnesota—December 2020–January 2021. MMWR Morb Mortal Wkly Rep, 70(8): 278.
• Harrison EA, Wu JW. 2020. Vaccine confidence in the time of COVID-19. Eur J Epidemiol, 35(4): 325-330.
• Lumley SF, O’Donnell D, Stoesser NE, et al. 2021. Antibody status and incidence of SARS-CoV-2 infection in health care workers. N Engl J Med, 384(6): 533-540.
• Siracusano G, Pastori C, Lopalco L. 2020. Humoral immune responses in COVID-19 patients: a window on the state of the art. Front Immunol, 11: 1049.
• Souza WM, Amorim MR, Sesti-Costa R, et al. 2021. Neutralisation of SARS-CoV-2 lineage P. 1 by antibodies elicited through natural SARS-CoV-2 infection or vaccination with an inactivated SARS-CoV-2 vaccine: an immunological study. Lancet Microbe, 2(10): e527-e535.
• Tanriover MD, Doğanay HL, Akova M, et al. 2021. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet, 398(10296): 213-222.
• WHO. 2020. https://www.who.int/news-room/q-a-detail/coronavirus-disease-(covid-19)-vaccines (Erişim tarihi: 19 Ağustos 2023).
• WHO. 2023. https://covid19.who.int/. (Erişim Tarihi: 17 Ağustos 2023).
• Yang HS, Costa V, Racine-Brzostek SE, et al. 2021. Association of age with SARS-CoV-2 antibody response. JAMA Netw Open, 4(3): e214302-e214302.
• Zee JS, Lai KT, Ho MK, et al. 2021. Serological response to mRNA and inactivated COVID-19 vaccine in healthcare workers in Hong Kong: decline in antibodies 12 weeks after two doses. Hong Kong Med J, 27(5): 380.
• Zhang Y, Zeng G, Pan H, et al. 2021. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis, 21(2): 181-192.